Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Avono Health vs Zealthy

Avono Health
Graded #361

Higher grade

vs+12
Zealthy
Graded #496

Lower grade

The verdict

Avono Health takes it — 58.7/100 to 46.7/100.

Avono Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fully online compounded GLP-1 telehealth with transparent, tiered pricing — microdose and standard semaglutide and tirzepatide in both injection and oral forms — plus US-licensed clinicians, 24/7 messaging…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAvono Health +4
30
26
Dose & formulationAvono Health +11
75
64
Clinical oversightAvono Health +39
80
41
Labs & monitoringEven
53
53
FulfillmentAvono Health +5
71
66
Contract termsAvono Health +6
47
41
Avono Health · left barZealthy · right bar

The numbers

MetricAvono HealthZealthy
WeighScore58.7/10046.7/100
GradeCC
Scorecard rank#361#496
Semaglutide$269/mo (compounded)$286/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$349/mo (compounded)$351/mo (starting dose, plus a separate fee, compounded)
CoverageCoverage not published34 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Avono Health

Graded #361 · C

Strengths

  • Transparent tiered pricing from $179/mo (microdose semaglutide injection)
  • Full compounded range — semaglutide and tirzepatide, injection and oral, microdose and standard
  • Free and discreet shipping; 24/7/365 messaging support; 100% online
  • US-licensed clinicians and pharmacies; bundle discounts at 3/6/12 months

Where it loses points

  • Medications are compounded, not FDA-approved brand-name
  • Compounding pharmacy not publicly named
  • State availability not published
  • Newer brand with limited independent review history
Zealthy

Graded #496 · C

Strengths

  • Serves 34 states — meaningful nationwide footprint
  • Asynchronous model removes friction for patients who don't want a video visit
  • Independent licensed prescribers retain full clinical authority

Where it loses points

  • Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
  • Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
  • Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
  • Recently rebranded to Gronk Inc. amid active enforcement
  • FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard